| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
619.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.17 - $24.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
45,000 |
180,115 |
180,115 |
210,533 |
| Total Sell Value |
$838,035 |
$3,323,210 |
$3,323,210 |
$4,306,417 |
| Total People Sold |
1 |
2 |
2 |
3 |
| Total Sell Transactions |
3 |
8 |
8 |
15 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Migausky George V |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
11,286 |
|
- |
|
| Bennett Jean |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
11,286 |
|
- |
|
| Fox Allan M. |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
11,286 |
|
- |
|
| Glucksmann Alexandra |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
11,286 |
|
- |
|
| Tasse Daniel |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
11,286 |
|
- |
|
| Zachary Jennifer |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
14,296 |
|
- |
|
| Karabelas Argeris N |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
11,286 |
|
- |
|
| Stump David C |
|
– • – |
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
11,286 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-05-14 |
4 |
AS |
$15.81 |
$237,222 |
D/D |
(15,000) |
408,035 |
|
-11% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-05-14 |
4 |
OE |
$3.76 |
$56,400 |
D/D |
15,000 |
423,035 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-04-15 |
4 |
AS |
$18.19 |
$272,871 |
D/D |
(15,000) |
408,035 |
|
-22% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-04-15 |
4 |
OE |
$3.76 |
$56,400 |
D/D |
15,000 |
423,035 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2024-03-19 |
4 |
OE |
$3.76 |
$75,354 |
D/D |
20,041 |
246,534 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-03-14 |
4 |
AS |
$21.86 |
$327,942 |
D/D |
(15,000) |
408,035 |
|
-36% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-03-14 |
4 |
OE |
$3.76 |
$56,400 |
D/D |
15,000 |
423,035 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2024-03-05 |
4 |
AS |
$28.36 |
$365,220 |
D/D |
(12,878) |
107,192 |
|
-43% |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2024-03-05 |
4 |
OE |
$22.25 |
$286,536 |
D/D |
12,878 |
120,070 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-02-14 |
4 |
AS |
$16.47 |
$251,349 |
D/D |
(15,000) |
408,035 |
|
-16% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-02-14 |
4 |
OE |
$3.76 |
$56,400 |
D/D |
15,000 |
423,035 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-01-16 |
4 |
AS |
$15.18 |
$682,992 |
D/D |
(45,000) |
408,035 |
|
-2% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-01-16 |
4 |
OE |
$3.76 |
$169,200 |
D/D |
45,000 |
453,035 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2024-01-03 |
4 |
AS |
$17.39 |
$299,789 |
D/D |
(17,237) |
107,192 |
|
-9% |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
32,051 |
124,429 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2024-01-02 |
4 |
D |
$17.95 |
$186,411 |
D/D |
(10,385) |
92,378 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
64,103 |
408,035 |
|
- |
|
414 Records found
|
|
Page 1 of 17 |
|
|
0.32 (2.33%) 
